– Partial cellular reprogramming with a realistic path to in vivo therapies.
– Organ-on-a-chip systems.
– In vivo delivery platforms for epigenetic or gene-editing longevity therapies.
– Blood and plasma-derived therapies with rigorous clinical endpoints beyond “feeling better”.
– Organ-scale replacement technologies that can integrate into existing surgical workflows.